Menzies-Gow A, Wechsler ME, Brightling CE, et al. Long-term safety and efficacy of
tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised,
placebo-controlled extension study. Lancet Respir Med 2023; published online Jan 23.
https://doi.org/10.1016/S2213-2600(22)00492-1 In this Article s appendix, table s7
should have read “n=840” participants in the all tezepelumab group for the pooled
NAVIGATOR and SOURCE population and the last line of the legend for figure s2 should
have read “(E; data from D were not included; same as the placebo then tezepelumab
group)”.
Tezepelumab treatment was well tolerated for up to 2 years and resulted in sustained,
clinically meaningful reductions in asthma exacerbations in individuals with severe,
uncontrolled asthma. These findings are consistent with previous randomised, placebo-controlled
studies and show the long-term safety and sustained efficacy of tezepelumab in individuals
with severe, uncontrolled asthma.
Usual interstitial pneumonia (UIP) is characterised by a distinctive morphological
and radiological appearance that was considered the pathognomonic hallmark of idiopathic
pulmonary fibrosis (IPF). However, this peculiar lung remodelling pattern is also
seen in other fibrotic interstitial lung diseases, including hypersensitivity pneumonitis,
and connective tissue diseases. In this Personal View, we advocate the designation
of a UIP pattern as a single, discrete diagnostic entity, amalgamating its primary
form and secondary processes in disorders such as hypersensitivity pneumonitis (hypersensitivity
pneumonitis with UIP), rheumatoid arthritis (rheumatoid arthritis with UIP), and others.
We thank Saurav Paul and colleagues for their response to our Correspondence.1 Our
original Correspondence was written at a time when scarce scientific information was
available on this uncommon presentation referred to as tomato flu; hence we included
media reports in our references. The main aim of our Correspondence was to increase
awareness of this unusual presentation, based on the information available to us at
the time; however, we appreciate that discussion of the COVID-19 pandemic in relation
to tomato flu might have caused unnecessary concern.
Heterogeneity is a familiar concept to paediatric intensive care physicians, because
patients, pathologies, and treatments vary both within the paediatric intensive care
unit (PICU) and within a given disease process. Paediatric acute respiratory distress
syndrome (ARDS) typifies this problem. Children with ARDS vary in terms of age (and
therefore lung development), underlying cause (pneumonia, sepsis, or trauma), pre-existing
comorbid conditions, and baseline immunological state. There is not one pathway by
which ARDS occurs or manifests, as indicated by the identification of hyperinflammatory
and hypoinflammatory subtypes in adults and children.